FDA Seeks Input on Biologics License Paperwork
Published Date: 7/6/2026
Notice
Summary
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Paperwork Burden for Biologics Makers
If you are a licensed manufacturer of biological products, the FDA estimates there are 371 respondents who will file an estimated 70,946 total annual responses, which together require about 860,170 total burden hours each year. These reporting and recordkeeping requirements come from 21 CFR parts 600-680 and 601 and are tied to Biologics License Applications (BLAs).
Standard Forms and Electronic Filing Rules
The FDA requires use of specific forms for BLAs, including Form FDA 356h, Form FDA 2252, Form FDA 2253, and Form FDA 3674, and permits submission via the Electronic Submission Gateway (ESG) for which respondents must create and maintain a user account. FDA states that using Form FDA 356h helps ensure applications are complete and may avoid delays in review.
Net Annual Response and Hour Adjustments
FDA reports cumulative adjustments that result in an average decrease of 2,168 responses and an average increase of 29,133 burden hours annually for this collection. These adjustments change how much time respondents must spend on their BLA-related submissions each year.
Notify Agents on License Suspension
Under 21 CFR 601.6(a), licensed firms must notify selling agents and distributors if a license is suspended. FDA estimates this third-party disclosure will result in about 20 disclosures (0.33 hours each) totaling roughly 7 hours annually for applicable respondents.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
Previous / Next Documents
Previous: 2026-13532 — Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Modify the NYSE American Options Fee Schedule Regarding Fees and Rebates Applicable to Manual Transactions
Starting now, NYSE American is changing how it charges fees and gives rebates for manual options trades. Market Makers will see updated fees on non-Penny stocks, and Floor Brokers will get new rebates when they trade with Market Makers on the floor. These changes kick in immediately and could affect how much traders pay or earn during manual transactions.
Next: 2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!